A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)
Latest Information Update: 25 May 2026
At a glance
- Drugs Immunoglobulin G (Primary) ; Rituximab (Primary)
- Indications Psychotic disorders
- Focus Therapeutic Use
- Acronyms SINAPPS2
Most Recent Events
- 22 May 2026 Planned End Date changed from 31 Mar 2027 to 30 Apr 2027.
- 22 May 2026 Planned primary completion date changed from 31 Mar 2027 to 30 Apr 2027.
- 22 May 2026 Status changed from recruiting to active, no longer recruiting.